Home
News
Create
Screeners
Insights
Sandu Pharmaceuticals
43.
70
+0.70
(+1.63%)
Market Cap
₹42.20 Cr
PE Ratio
27.14
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.63%
1M
-2.02%
6M
-12.72%
1Y
-24.46%
5Y
+46.40%
View Company Insights
Latest news about Sandu Pharmaceuticals
Sandu Pharmaceuticals Seeks Shareholder Approval for Promoter Reclassification
Oct 17, 2025
Sandu Pharmaceuticals Limited has initiated a process to reclassify Akshath Finvest and Properties Private Limited from the promoter category to public category. The company is seeking shareholder approval through a postal ballot. Akshath Finvest currently holds 4,94,182 shares (5.12% of paid-up equity share capital). The Bombay Stock Exchange has granted approval for the reclassification, subject to shareholder consent. E-voting is scheduled from October 20, 2025, to November 18, 2025, with results expected by November 20, 2025. The reclassification aligns with SEBI's Listing Obligations and Disclosure Requirements Regulations.
Sandu Pharmaceuticals Board Approves Postal Ballot for Promoter Reclassification
Oct 14, 2025
Sandu Pharmaceuticals Reports 33.8% Jump in Q1 Net Profit Despite Revenue Decline
Aug 15, 2025
Sandu Pharmaceuticals Reports Q1 Profit, Declares Dividend, and Schedules 40th AGM
Aug 13, 2025
Sun Pharma's Halol Facility Faces FDA Scrutiny; Leadership Transition Announced
Jun 16, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation